Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Former Drug Abuse Cmte. Chair Asks FDA To Reconsider Need For Panel

Executive Summary

FDA should reconsider its decision to disband the Drug Abuse Advisory Committee, former chair Eric Strain, MD, Johns Hopkins University, suggested during a Peripheral & Central Nervous System Drugs Advisory Committee meeting June 6.

You may also be interested in...



Orphan Xyrem Daytime Sleepiness Confirmatory Data Expected In 2002

Results from Orphan Medical's Xyrem trial examining daytime sleepiness in patients with narcolepsy are expected in the third quarter of 2002.

Xyrem Risk Management Plan Should Limit Drug's Use To Cataplexy - Cmte.

Orphan Medical's Xyrem risk management program should limit physician use of the gamma hydroxy butyrate product to treatment of cataplexy, FDA's Peripheral & Central Nervous System Drugs Advisory Committee said at its June 6 meeting.

Orphan Xyrem Daytime Sleepiness Confirmatory Data Expected In 2002

Results from Orphan Medical's Xyrem trial examining daytime sleepiness in patients with narcolepsy are expected in the third quarter of 2002.

Related Content

UsernamePublicRestriction

Register

PS037986

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel